<SEC-DOCUMENT>0001104659-25-118588.txt : 20251205
<SEC-HEADER>0001104659-25-118588.hdr.sgml : 20251205
<ACCEPTANCE-DATETIME>20251205060105
ACCESSION NUMBER:		0001104659-25-118588
CONFORMED SUBMISSION TYPE:	424B3
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20251205
DATE AS OF CHANGE:		20251205

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CAPRICOR THERAPEUTICS, INC.
		CENTRAL INDEX KEY:			0001133869
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-290179
		FILM NUMBER:		251551094

	BUSINESS ADDRESS:	
		STREET 1:		10865 ROAD TO THE CURE
		STREET 2:		SUITE 150
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		(310) 358-3200

	MAIL ADDRESS:	
		STREET 1:		10865 ROAD TO THE CURE
		STREET 2:		SUITE 150
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Nile Therapeutics, Inc.
		DATE OF NAME CHANGE:	20070920

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SMI PRODUCTS INC
		DATE OF NAME CHANGE:	20010206
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B3
<SEQUENCE>1
<FILENAME>capr-20251205x424b3.htm
<DESCRIPTION>424B3
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  11.1.0.82--><!--Created on: 12/5/2025 03:43:57 AM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Filed Pursuant to Rule 424(b)(3)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Registration No. 333-290179</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="capr-20251205x424b3001.jpg" alt="Graphic" style="display:inline-block;height:50.24pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:149.98pt;"></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">PROSPECTUS SUPPLEMENT NO. 1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">TO PROSPECTUS DATED SEPTEMBER 23, 2025</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">This Prospectus Supplement No. 1 supplements and amends the prospectus dated September 23, 2025 (the&#160;&#8220;Prospectus&#8221;), covering the offering, issuance and sale of up to a maximum aggregate offering amount of $150,000,000 (the &#8220;Maximum Offering Amount&#8221;) of our common stock, par value $0.001 per share (&#8220;Common Stock&#8221;), that may be issued and sold under an equity distribution agreement, dated September 10, 2025, with Piper Sandler &amp; Co. and Oppenheimer &amp; Co. Inc. (the &#8220;ATM Facility&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Effective as of December 5, 2025, we have reduced the Maximum Offering Amount to $125,000,000. As of the date of this prospectus supplement, 2,682,307 shares of our Common Stock have been sold under the ATM Facility, for aggregate gross proceeds of approximately $77.5 million, before deducting sales agents&#8217; commissions, meaning that we will have approximately $47.5 million remaining available under the Maximum Offering Amount.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">You should read this prospectus supplement, together with additional information described under the headings &#8220;Information Incorporated by Reference&#8221; and &#8220;Where You Can Find More Information&#8221; in the Prospectus carefully before you invest in our securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Investing in our securities involves a high degree of risk. Before making any investment in our securities, you should consider carefully the risks and uncertainties described in the section entitled &#8220;Risk Factors&#8221; beginning on page S-5 of the Prospectus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">The date of this prospectus supplement is December 5, 2025.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>capr-20251205x424b3001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 capr-20251205x424b3001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !# ,@# 2(  A$! Q$!_\0
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M_!7.&+PT%C2_LF?5XX/N[VL&>3=CH25B<_[1]Z]>_P""HO\ R:7JO_84LO\
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MRO/C/^VI!9MX=7X2Z,^L@>2/$$11HB?^>@S/Y>?J,?[/:L7X7?\ *6;XA?\
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M ()Z_"WQ3\(/V?%T#Q?I$NB:O_:US<?99G1F\M@FULJ2.<'O4/[8_P"R1?\
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M,1@* "<]R,U/^R[XFU'QA9^)M2U69)[P74<.^.%(5*A-PRJ*JDY8_-C)X!.
D,%%>KC*5.%/%<L4K.-M/0\W"U)RGAN:3=U(]RHHHKY(^G/_9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
